Clinical Trials Browser

Sarcoma × CTLA-4 Antigen × Clear all

NCT03449108 2025-11-21

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05836571 2025-10-20

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Phase 2 Active not recruiting

66 enrolled

Sarcoma

Sarcoma, Histiocytoma, Malignant Fibrous

NCT04118166 2023-12-12

Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma

Phase 2 Completed

30 enrolled 9 charts

Sarcoma

NCT02500797 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

Phase 2 Completed

164 enrolled 22 charts

Sarcoma

Bone Neoplasms, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT01643278 2017-01-10

Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic

Phase 1 Completed

29 enrolled

GastrointestinalSarcoma

Sarcoma, Gastrointestinal Stromal Tumors